Expert Insights

How digital therapy benefits patients, providers, and the health ecosystem

Evidence-based, personalized treatment can increase engagement and improve outcomes
Experts on this topic

**Dr. Bernd Schneidinger**
International Business Lead
Roche Diabetes Care GmbH
Bernd.schneidinger@roche.com

Dr. Bernd Schneidinger is an International Business Lead at Roche Diabetes Care GmbH. A biologist by training, his recent work focuses on how digital therapeutics can help people with diabetes better manage the disease, and improve and maintain a healthy blood glucose range.

**Matthias Schieker**
Executive Director, Translational Medicine Musculoskeletal Diseases
Novartis Institute for Biomedical Research (NIBR)
matthias.schieker@novartis.com
https://www.linkedin.com/in/schieker/

Matthias Schieker is a Professor for regenerative medicine, physician-scientist, surgeon, and innovator. His professional experience includes academic medicine and leadership positions in both pharmaceutical and biotech companies. Matthias leads a cross-functional strategy team within Novartis that’s focused on digital technologies and innovative solutions for mobility.

**Delphine Hajaji**
Venture Fund Partner
UCB
delphine.hajaji@ucb.com
https://www.linkedin.com/in/delphine-hajaji-b904792/

Delphine Hajaji has 14 years of digital/tech experience across various industries, the past seven in pharma. As Global Senior Director for the Technology Practice iPVU and nPVU at UCB, she was responsible for the data and technology strategy and implementation of all non-drug solutions: biosensors, e-devices, diagnostic tools, and companion apps.
Digital therapy is an emerging approach to effective delivery of behavioral therapy, and fundamentally complementary to pharmacotherapy.

Talking points

A combination of AI and sensor technologies can augment existing therapy to benefit both patients and healthcare payers
Accumulated patient data enables the creation of individualized solutions. It also allows healthcare providers to optimize treatment with a goal of better outcomes and lower costs.

Life sciences companies are building capabilities commonly found within IT companies, and vice versa
Digital therapy is a useful addition to current standard care. For the life sciences industry, it enables new “beyond the pill” business models centered on support services and advice tailored to the patient.

Proven clinical effectiveness and regulatory oversight are providing guardrails to healthcare’s “digital revolution”
Digital therapies must undergo clinical studies, show positive health outcomes, and acquire approval to earn credibility among healthcare providers and payers as an accepted medical treatment.

The future of disease management is digital
Digital products are assuming an ever-greater role in healthcare, from artificial intelligence (AI)-enabled apps that help manage patient health, to digital sensors and wearables that create terabytes of granular data. When it comes to how digital therapy may impact healthcare in the coming years, what stands out are the benefits of personalization and individualization to reinforce healthy behaviors, and the promise of greater patient engagement. And although challenges remain, the healthcare industry is optimistic that digital intervention will improve patient outcomes.

Augmenting therapy with AI and digital sensors
To better understand the potential of digital therapy, consider some of its most valuable clinical applications, such as diabetes and chronic pulmonary disease care, where opportunities to provide true relief currently abound.

More than 400 million people live with diabetes worldwide, and the prevalence is predicted to rise. People with diabetes need to manage their blood sugar levels through lifestyle changes, oral medication, or insulin injection. But optimal daily insulin dosing may constantly vary, which can strongly impact quality of life. AI-enabled capabilities—or the emulation of natural intelligence by a machine—and digital sensors can measure, monitor, predict and respond to daily blood glucose measurements. It can also perform personalized analyses to determine whether and when insulin dose adjustments are needed in real time by identifying when a patient experiences out-of-range highs or lows. Patients whose insulin regime is guided by AI-based software and individualized algorithms might not only achieve blood glucose control more easily but with ongoing personalized dose adjustments, successfully maintain optimal levels long term, and lower their risk of complications.
What are digital therapeutics?

Digital therapeutics, also known as DTx or digital therapy, deliver software-generated interventions directly to patients to prevent, manage, or treat a medical disorder or disease. DTx, like other therapeutic interventions, must demonstrate robust, measurable clinical outcomes, coverage by payers, and regulatory approval.

For life sciences companies, trials become more targeted by identifying patients in need, stratifying the patient population, and using this information for predictive modeling. For payers, targeted treatment in an in-home environment help prevent disease progression. Digital therapy benefits are expected to lead to more accurate treatments for patients, an overall reduction of diseases through prevention and early intervention, and better value-based health-care models.

Why now?

The exponential decrease in computation costs, the growing capital needed to develop a molecule-based drug, better access to healthcare data, and a strong decrease in sensor technology costs have enabled the delivery of high-quality, clinically validated therapeutic interventions at unprecedented scale. Technological advancements and a new policy landscape will likely lead to a surge in digital health interventions addressing a wider range of health conditions.

Pairing digital sensors and respiratory drugs can also help patients with chronic obstructive pulmonary disease (COPD). A small sensor attached at the top of an inhaler automatically records when a patient uses it. Data is collected and sent to a mobile app to track medication use and — should the patient choose to share their data with a physician — provide personal feedback and insights on how to limit long-term complications. Approved by the US Food and Drug Administration (FDA), the sensor and inhaler combination has shown a 58 percent improvement in medication adherence, 48 percent increase in symptom-free days, and 53 percent reduction in emergency room visits.

Treating human behaviors and human biology

Digital therapy is no match for medicine. It’s not a direct replacement for a pharmaceutical intervention, or meant to provide a placebo effect, but may be a useful adjunct to traditional therapy. For those with mood disorders, behavioral change may be less effective than antidepressants. Same for a smoker trying to quit; nicotine replacement may be more beneficial. But a doctor might include a prescription for, say, a mobile app in addition to medicine.

Medication adherence is one of the behaviors that often employ strategies based on cognitive behavioral therapy (CBT), or changing the way one thinks and behaves. CBT is an effective way to treat a range of behaviors and deliver a number of patient therapies, including drug adherence, but it’s cumbersome to deliver and often not evidence-based in practice.
Digital platforms like mobile apps can help encourage and enhance behavioral change with improved access to, engagement with, and quality control of a therapy. For example:

– Sandoz, a division of Novartis and in collaboration with Pear Therapeutics, has commercialized a software-only therapeutic to treat Substance Use Disorder, a disease caused by the recurrent use of cocaine, cannabis, or stimulants.7 Treatment includes CBT delivered through mobile and desktop applications, monitoring patients in real time, detecting day-to-day behavioral changes, and enhancing treatment outcomes. When used with outpatient therapy and contingency management, it can significantly improve abstinence and retention compared to outpatient therapy alone.8

– Digital sleep-improvement program Sleepio seeks to replace sleeping medication with digital therapy delivered through a web-based application. Sleepio uses CBT to help conquer insomnia with coaching to conquer insomnia-related factors like negative thoughts, emotions or behaviors. The therapy also trains positive associations to the sleeping environment and regular bedtime routines. In the first placebo-controlled randomized clinical trial, 75 percent of patients with persistent sleep problems saw an improvement in their sleep.9

Blurring the line between treatment and technology

Healthcare professionals who regularly apply or prescribe digitally supported therapy rank individualized therapy and greater patient engagement as primary benefits, along with improved patient outcomes (see Figure 1).

While some digital technologies use cases fall into distinct categories of behavioral modification or therapy augmentation, there are cases that support both. For example, loss of mobility is an ever-increasing concern for both the aging population and post-surgery rehabilitation.

Figure 1

What main benefits will be realized by digital therapies?

<table>
<thead>
<tr>
<th>Benefit</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individualized therapy</td>
<td>63%</td>
</tr>
<tr>
<td>Greater patient engagement</td>
<td>61%</td>
</tr>
<tr>
<td>Improved outcomes</td>
<td>56%</td>
</tr>
<tr>
<td>Reduced cost of care</td>
<td>43%</td>
</tr>
<tr>
<td>New medical insights</td>
<td>30%</td>
</tr>
<tr>
<td>Better reach of care</td>
<td>26%</td>
</tr>
</tbody>
</table>

Source: IBM mini pulse survey of healthcare and life sciences professionals in Europe and the US.

Digital solutions can identify, monitor, and motivate patients through natural disease progression, or offer guidance through a treatment and rehabilitation exercise regime. The recovery period can be observed, measured and tracked across platforms. By watching for changes in behavior or physical well-being, such solutions let patients, caregivers and family members see how the patient is doing and enable new treatment approaches with innovative digital therapeutic interventions.

Paramount to ongoing patient monitoring and treatment is developing specific digital endpoints, or digital biomarkers, that measure mobility using sensor data gathered by wearable devices. As pharmaceutical companies experiment with novel wearable technologies, and “health tech” businesses develop medical-grade devices and software, the lines of data ownership become blurred.
To be competitive in the evolving field of digital health, life sciences companies like Novartis are spearheading digital organizations and building in-house data science capabilities like those commonly found within technical organizations. Likewise, technology companies are taking on capabilities traditionally reserved for life sciences firms, such as building medical devices and running observational studies. For example:

– Two new features of the Apple Watch Series 4—heart monitoring capabilities including electrocardiogram (EKG) and irregular rhythm notification functions, and one that can detect hard falls and summon help if needed—have been cleared by the US Food and Drug Administration (FDA) as a grade 2 medical device.\(^\text{10}\)

– Verily Life Sciences, formerly Google Life Sciences, runs Project Baseline, an observational study to track the health of 10,000 participants over time. The goal is to collect comprehensive health data, develop a well-defined reference, or baseline, of good health, and use it as a compass to point the way to disease prevention.\(^\text{11}\)

– The worlds of pharmaceutical and technology are also joining forces. Amazon and Merck jointly launched the Alexa Diabetes Challenge, where participants create voice-command technology to help patients with diabetes better manage their disease.\(^\text{12}\)

Challenges and the next chapter in healthcare

Regulation is one challenge inhibiting the swift development and creation of digital therapies. Technology is evolving more quickly than the formalization of required legal steps to clinically approve it. Nevertheless, regulations are a crucial prerequisite and must modernize to keep pace with digital innovation. Digital therapies are regulated differently than drugs since they are dynamic and ever-learning. The FDA is developing and implementing strategies, policies, and processes to regulate AI in medical devices.\(^\text{13}\)

Then, there’s the matter of public perception related to concerns about patient and pharmaceutical data sharing. The General Data Protection Regulation (GDPR) sets stringent guidelines for collecting and processing personal information in Europe, while China and Russia don’t allow hosting of data outside their borders. In the US, the Health Insurance Portability and Accountability Act (HIPAA) helps consumers maintain insurance coverage by protecting confidentiality.

Digital therapy has yet to show overwhelming commercial results. Accordingly, pharmaceutical companies won’t or can’t afford to invest without a clear business case on how to commercialize it.

The following is vital to further progress digital therapies:

– Understand what could be improved. Healthcare companies need a firm grasp on information technologies. Pharmaceutical companies need to bolster their scientific and medical strengths with technology, data, and analytics expertise. While partnerships become more important, pharmaceutical companies will have to find the right balance between internalizing core competencies, and bolstering skills and agility through interdisciplinary alliances and external collaborations.

– Explore the potential of digital approaches early. Throughout the development process, life sciences companies need to gather evidence for improved outcomes of digitally supported therapies. Ultimately, they will explore new digital endpoints, generate more comprehensive data, and drive more targeted studies.

– Recognize that people drive technology. Collaboration puts smart people together to create smart solutions. With worldwide technology hubs to share knowledge and leading practices, participation of pharmaceutical companies, scientists, platform and ecosystem players, payers, regulators, and data and analytics specialists and AI pioneers is needed.
Key questions to consider

» Use cases show that the burden of chronic conditions on both patients and healthcare systems can be elevated with digital therapies. What other areas of healthcare might benefit?

» Obstacles remain that are preventing faster uptake of digital therapies for healthcare. Can these obstacles be overcome?

» How prepared is your industry to unlock the potential that exists between the technology, clinical need, and path to market?

Contributors

The IBM Institute for Business Value thanks Lars Böhm, Alexander Büsser, Karen Pesse, Sumehra Premji, and Yannick Klopfenstein for their contributions in developing this Expert Insights report, and Anil Jain and Joris Van Dam for their shared expertise.

About Expert Insights

Expert Insights represent the opinions of thought leaders on newsworthy business and related technology topics. They are based upon conversations with leading subject matter experts from around the globe. For more information, contact the IBM Institute for Business Value at ibv@us.ibm.com.
© Copyright IBM Corporation 2019

IBM Corporation
New Orchard Road
Armonk, NY 10504
Produced in the United States of America
April 2019

IBM, the IBM logo, ibm.com and Watson are trademarks of International Business Machines Corp., registered in many jurisdictions worldwide. Other product and service names might be trademarks of IBM or other companies. A current list of IBM trademarks is available on the web at “Copyright and trademark information” at: ibm.com/legal/copytrade.shtml.

This document is current as of the initial date of publication and may be changed by IBM at any time. Not all offerings are available in every country in which IBM operates.

THE INFORMATION IN THIS DOCUMENT IS PROVIDED “AS IS” WITHOUT ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND ANY WARRANTY OR CONDITION OF NON-INFRINGEMENT. IBM products are warranted according to the terms and conditions of the agreements under which they are provided.

This report is intended for general guidance only. It is not intended to be a substitute for detailed research or the exercise of professional judgment. IBM shall not be responsible for any loss whatsoever sustained by any organization or person who relies on this publication.

The data used in this report may be derived from third-party sources and IBM does not independently verify, validate or audit such data. The results from the use of such data are provided on an “as is” basis and IBM makes no representations or warranties, express or implied.

Notes and sources
1 IBM mini-pulse survey of 51 healthcare and life sciences professionals in Europe and the US. November 2018.
2 Ibid.
8 Ibid.
13 “Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s new actions under the Pre-Cert Pilot Program to promote a more efficient framework for the review of safe and effective digital health innovations.” FDA. January 2019. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm629306.htm